Phase 2 N=60 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Esophageal Neoplasms · Stomach Neoplasms · Neoplasm Metastasis
Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Gastroesophageal Cancer · Gastric Cancer
Primary: Progression Free Survival — 7.8 months
Phase 2 N=39 FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Gastro-Esophageal Junction Adenocarcinoma · Gastric Cancer
Primary: Objective Response Rate — 15 Participants
Phase 2 N=35 Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stomach Cancer · Gastric (Stomach) Cancer · Neoplasm of Cardioesophageal Junction
Primary: Progression-Free Survival (PFS) — 9 Participants
Phase 1 N=20 TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma · GastroEsophageal Cancer
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants
Phase 3 N=904 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
Gastric Cancer
Primary: Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments — 4.4; 5.6 months — p=0.3158
Phase 2 N=49 Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
Malignant Solid Tumour · Gastroesophageal Cancer
Primary: The Incidence of Dose Limiting Toxicities (DLT) in Phase I Dose Escalation — 0; 0; 1 participants
Phase 3 N=628 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
Esophageal Carcinoma · Esophagogastric Junction Carcinoma
Primary: Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus — 8.2; 7.1 Months — p=0.00894
Phase 2 N=48 Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Stomach Neoplasms · Esophageal Neoplasms
Primary: 6 Month Progression Free Survival — 79 percentage of participants
Phase 2 N=39 Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach · Intestinal Adenocarcinoma of the Stomach
Primary: Response Rates (RR) in Metastatic Gastric/GE Junction Tumors — 2; 9; 3; 16 participants
Phase 2 N=44 Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Metastatic Gastric Cancer · Advanced Unresectable Gastric Cancer
Primary: The Proportion of Patients With Objective Response (Complete Response or Partial Response) — 0.409 Proportion of patients — p=0.0012
Phase 2 N=24 Phase II Study of Irinotecan and Panitumumab
Esophageal Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Phase 2 N=202 S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer · Gastric Cancer
Primary: Progression-free Survival (PFS) in High-ERCC1 Patients — 4.7; 5.3 months — p=0.83
Phase 2 N=80 Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: RR — 15 Participants
Phase 2 N=39 Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Esophageal Cancer · Gastric Cancer
Primary: Time to Progression — 6.6 months
Phase 2 N=64 FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: 6-month Progression-free Survival (PFS) — 60.5; 57.1 percent probability — p=0.72
Phase 2 N=40 Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Gastric Adenocarcinoma · Gastro-esophageal Junction Adenocarcinoma
Primary: Progression-free Survival (PFS) — 5.257 months
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Phase 2 N=40 Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Gastric Cancer
Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants
Phase 3 N=592 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Programmed…
Phase 2 N=34 Docetaxel and Epirubicin in Advanced Gastric Cancer
Stomach Neoplasms
Primary: Overall Survival — 13.4 month
Phase 2 N=18 Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Gastric Adenocarcinoma · Esophageal Adenocarcinoma · Metastasis
Primary: Best Objective Response Rate (bORR) — 61; 50 Percentage of participants
Phase 2 N=34 Nintedanib in Patients With Advanced Esophagogastric Cancer
Esophagogastric Adenocarcinoma
Primary: 6-month Progression-free Survival (PFS) — 1.9 months
Phase 2 N=3 Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Recurrent Esophageal Carcinoma
Primary: Progression-free Survival (PFS) — 0 Participants
Phase 2 N=54 RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
Stomach Neoplasm
Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants
Phase 3 N=432 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Primary: Overall Survival (OS) — 12.52; 11.76 months — p=0.5625
Phase 2 N=65 Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
Gastroesophageal Cancer
Primary: Progression-Free Survival (PFS) — 3.8 months
Phase 3 N=738 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Gastric Neoplasms · Gastroesophageal Junction Adenocarcinoma
Primary: Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICR — 10.0; 8.1 Months — p=0.0002
Phase 2 N=36 KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer
Gastric Cancer · Esophagus Cancer
Primary: Months of Progression-free Survival (PFS) — 7.6 months — p=0.02
Phase 2 N=23 TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Gastric Cancer
Primary: Overall Survival — 4.8 months